Popular Stories

Biopharmaceutical Tag

  • All
  • Beauty
  • Biotechnology
  • Cannabis
  • Communications
  • Education
  • Energy
  • Entertainment
  • Environment
  • ETFs
  • Finance
  • Fitness
  • Food and Beverage
  • Healthcare
  • Hospitality
  • Insider Trading
  • Investing Ideas
  • Macro
  • Market Insight
  • Miscellaneous
  • Power
  • Real Estate
  • Retail
  • Sectors
  • Security
  • Startups
  • Technologies
  • Trending
  • Uncategorized
Initiates Make-or-Break Phase 3 Clinical Trials in AngelMan Syndrome

Ovid Therapeutics (NASDAQ: OVID), a biopharmaceutical company developing novel therapeutics for rare neurological disorders, announced the launch of a crucial phase 3 clinical trial in Angelman Syndrome named NEPTUNE. OV101, its lead candidate for  the treatment of syndrome and Fragile X Syndrome is a delta-selective...

Emerging treatment approaches in Pruritus

Pruritus is characterized by an uncomfortable and persistent urge to scratch caused either due to a skin disorder or an underlying systemic disease such as atopic dermatitis, mycoses, chickenpox, hepatitis, Jaundice, chronic renal failure, cholestasis or NASH. These can be chronic in nature and affect...

CHALLENGING INSOMNIA BY INNOVATIVE RE-ENGINEERING OF THE NEURAL PATHWAYS

The Global Market for Insomnia is estimated to reach $5,488 million by 2023 from $4,093 million in 2016 at a CAGR of 4.2% according to a report titled “Insomnia Market by Therapy Type [Non-pharmacological Therapy (Hypnotherapy, Cognitive Behavioral Therapy, Medical Devices, and Other Non-pharmacological Therapy) and Pharmacological Therapy (Prescription...

WordPress Video Lightbox Plugin